Stephan Windecker

In this prespecified secondary analysis of the FAVOR III China trial, QFR-guided PCI significantly reduced 3-year MACE compared to angiography-guided PCI in patients with multivessel disease, with consistent directional benefit regardless of MVD status.

Highlights potential risks of DES overlap; extends experimental data but leaves open relevance to contemporary stents.

May inform Evolut PRO selection in high-risk elderly patients; extends Level 5 evidence for sustained hemodynamics and improving regurgitation to 5 years.

In OHCA patients without ST-segment elevation, acute coronary occlusion occurs in about 1 in 5 patients regardless of hemodynamic stability, and is better predicted by initial chest pain or shockable rhythm.

Sirolimus-eluting stents are associated with exercise-induced paradoxic coronary vasoconstriction in adjacent vessel segments at 6 months, suggesting drug-induced endothelial dysfunction.

In patients with stable coronary artery disease, well-developed coronary collateral vessels are associated with a significantly reduced risk of future major cardiac ischemic events.

Registry study demonstrates favorable mid-term valve durability after transcatheter tricuspid replacement, indicating low rates of endocarditis and leaflet thrombosis.

IL-8 levels peak in the hyper-acute phase of AMI and are independently associated with 1-year mortality, providing early prognostic value before the rise of traditional cardiac injury markers like hsTnT.

4D flow CMR provides a novel paradigm for evaluating transcatheter aortic valve performance by assessing the restoration of physiological aortic flow.

Small aortic annulus was not associated with inferior 3-year TAVR outcomes; supports comparable recovery yet leaves valve-type interactions open for confirmation.

Highlights the continued necessity of randomized clinical trials over common sense and clinical observation to establish causal relationships in cardiovascular medicine.

TAVR in patients with low-flow, low-gradient aortic stenosis improves LVEF, but 2-year mortality is high and baseline dobutamine stress echocardiography fails to predict clinical outcomes or LVEF changes.

TAVR plus PCI offers a viable option versus SAVR plus CABG for intermediate-risk aortic stenosis with CAD; extends randomized evidence to revascularized cohorts.

Does not support ticagrelor monotherapy after 1-month DAPT post-PCI; fails to confirm superiority hypothesis in broad populations.

The CODE-EHR framework establishes minimum standards for using structured electronic healthcare records in clinical research to ensure robust and transparent evidence generation.